"It's already in your body and it's preventing": a qualitative study of African female adolescent's acceptability and preferences for proxy HIV prevention methods in Cape Town, South Africa.

Publisher: BioMed Central Country of Publication: England NLM ID: 100968562 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2458 (Electronic) Linking ISSN: 14712458 NLM ISO Abbreviation: BMC Public Health Subsets: MEDLINE

Original Publication: London : BioMed Central, [2001-

HIV Infections*/prevention & control ; HIV Infections*/drug therapy ; Pre-Exposure Prophylaxis*/methods ; Anti-HIV Agents*/therapeutic use; Humans ; Female ; Adolescent ; South Africa/epidemiology ; Cross-Over Studies ; Contraception/methods ; Contraceptive Agents/therapeutic use

Background: Advances in biomedical HIV prevention will soon offer young women a choice of HIV prevention methods, including various pre-exposure prophylaxis (PrEP) modalities such as daily oral pills, dapivirine vaginal ring, and long-acting injectable agents. By understanding preferences for contraceptive methods, we may draw analogies for the HIV prevention needs of young women. The UChoose Study was an open-label randomised cross-over study designed to evaluate the acceptability and preference for several contraceptive options as a proxy for HIV prevention methods that use similar types of administration. The study enrolled healthy HIV uninfected young women aged 15 to 19 years. At enrolment, participants were randomly assigned to a contraceptive method for a period of 16 weeks in the form of monthly Nuvaring® (vaginal ring), daily combined oral contraceptive (daily pills), or bi-monthly injectable contraceptive (injectable). After 16 weeks, participants crossed over to another contraceptive method, and those who had received the injectable and the daily pills received the vaginal ring for another 16 weeks, whereas those who had received the vaginal ring were able to choose between the injectable and daily pills, to ensure that all participants tried the vaginal ring-the least familiar option to the study population.
Results: Thirty-three participants were purposively recruited to participate in seven focus group discussions (FGD) and completed a pre-survey for their assigned group. Our sample comprised 14 participants randomised to use of the vaginal ring and daily pills and 19 participants randomised to use of the vaginal ring and injectable. For most participants, their preferences for a prevention method were based primarily on their desire to avoid negative aspects of one method rather than their positive user experience with another method. Most participants expressed initial hesitancy for trying new contraception method products; however, a lack of familiarity was moderated by a strong interest in diverse user-controlled prevention methods. Participants valued methods that had infrequent dosing and simplified use requirements. The injection and vaginal ring were preferred over daily pills as a potential HIV prevention method.
Conclusion: Expanding the availability of diverse products could provide adolescents with multiple choices in HIV prevention for the uninitiated.
Trial Registration: ClinicalTrials.gov ( NCT02404038 ). Registered March 31, 2015-Registered.
(© 2023. The Author(s).)

N Engl J Med. 2015 Feb 5;372(6):509-18. (PMID: 25651245)
Lancet. 2008 Aug 23;372(9639):669-84. (PMID: 18687459)
AIDS Behav. 2018 Jan;22(1):133-145. (PMID: 29052018)
AIDS Res Hum Retroviruses. 2018 Mar;34(3):254-260. (PMID: 28969432)
AIDS. 2018 Jul 17;32(11):1517-1525. (PMID: 29957723)
AIDS Care. 2013;25(2):133-50. (PMID: 22774763)
AIDS Behav. 2017 May;21(5):1325-1335. (PMID: 27900502)
PLoS One. 2018 Oct 31;13(10):e0204821. (PMID: 30379839)
AIDS Behav. 2017 May;21(5):1361-1375. (PMID: 27317411)
Int J Womens Health. 2019 Feb 07;11:97-107. (PMID: 30799959)
J AIDS Clin Res. 2017 Sep;8(9):. (PMID: 29201531)
BMC Public Health. 2018 Jan 26;18(1):183. (PMID: 29373958)
J Int AIDS Soc. 2019 May;22(5):e25282. (PMID: 31074936)
AIDS Behav. 2013 Jul;17(6):2162-72. (PMID: 23080358)
AIDS Behav. 2020 Mar;24(3):866-880. (PMID: 31111297)
Adv Drug Deliv Rev. 2015 Sep 15;92:146-54. (PMID: 25703190)
Arch Sex Behav. 2021 Oct;50(7):2921-2931. (PMID: 34561792)
J Acquir Immune Defic Syndr. 2014 Jul 1;66(3):324-31. (PMID: 25157647)
Qual Life Res. 2006 Dec;15(10):1621-31. (PMID: 17031502)
HIV AIDS (Auckl). 2019 Jul 31;11:179-192. (PMID: 31447590)
BMC Public Health. 2018 Mar 2;18(1):303. (PMID: 29499668)
AIDS Care. 2019 Oct;31(10):1207-1213. (PMID: 30822101)
Lancet. 2016 Jan 2;387(10013):53-60. (PMID: 26364263)
J Int AIDS Soc. 2018 Aug;21(8):e25170. (PMID: 30152004)
J Int AIDS Soc. 2020 Oct;23(10):e25626. (PMID: 33034421)
J Int AIDS Soc. 2018 Mar;21(3):e25094. (PMID: 29600595)
AIDS Behav. 2018 Aug;22(8):2662-2673. (PMID: 29560570)
Drugs. 2019 Aug;79(12):1263-1276. (PMID: 31309457)
PLoS One. 2012;7(1):e28238. (PMID: 22247757)
Sex Transm Infect. 2018 May;94(3):163-168. (PMID: 28756409)
J Int AIDS Soc. 2014 Sep 08;17(3 Suppl 2):19146. (PMID: 25224610)
AIDS Patient Care STDS. 2020 Mar;34(3):132-146. (PMID: 32202930)

R01 AI094586 United States AI NIAID NIH HHS

Keywords: Adherence; Adolescent girls; Contraception; HIV prevention; Preference; South Africa

ClinicalTrials.gov NCT02404038

0 (Contraceptive Agents)
0 (Anti-HIV Agents)

Date Created: 20231103 Date Completed: 20231106 Latest Revision: 20240210

20240210

PMC10621226

10.1186/s12889-023-16955-3

37919697